Pembrolizumab for relapsed or refractory Hodgkin lymphoma

Lancet Oncol. 2021 Jun;22(6):e234. doi: 10.1016/S1470-2045(21)00251-5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antineoplastic Agents, Immunological* / adverse effects
  • Brentuximab Vedotin
  • Hodgkin Disease* / drug therapy
  • Humans

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Brentuximab Vedotin
  • pembrolizumab